All In Biotech

Drug Trial Radar · NCT01179828

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain

Last checked: Nov 19, 2026Latest source record: Apr 6, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jul 2010

Primary completion

Apr 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Insel Gruppe AG, University Hospital BernAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Bern; University of Zurich; Aalborg University
First posted
Aug 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drug therapy in patients with chronic low back pain is a major challenge for physicians. One of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient. Usually one of the classes of pain medication is given to patients with a similar clinical picture, although different pain mechanisms may be responsible for this clinical picture. Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason why an unique drug produces different responses (from a lacking analgesic effect up to excessive effect or side-effects. Quantitative sensory testing is a method that documents alterations in the pain perception system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for anticipation of drug efficacy.

Conditions

  • Low Back Pain

Interventions

  • Oxycodone 15mgDrug

    15mg single administration p.o.

  • ClobazamDrug

    20mg single administration p.o.

  • ImipramineDrug

    75mg single administration p.o.

  • TolterodineDrug

    1 mg single administration p.o.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in NRS(pain scale) between measurement after and before drug administrationTime frame: 07/2012

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Andreas Siegenthaler

    Dep. of Anesthesiolgy and Pain Therapy, Bern University Hospital, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.